IP Library Granted Patent US 10,336,775
Granted Patent B2
US 10,336,775 · App. 15/507,375 · Granted Jul 2, 2019

Glycosidase inhibitors

Inventors: Anna Quattropani (Rolle, CH); Santosh S. Kulkarni (Bangalore, IN); Awadut Gajendra Giri (Bangalore, IN)
Assignee: Asceneuron SA
C07D513/04A61K31/454A61K31/496A61K31/497A61K31/498A61K31/501A61K31/506A61K31/517A61K31/519A61K31/5377A61K45/06C07D277/46C07D285/135C07D401/12C07D403/12C07D405/12C07D405/14C07D413/12C07D413/14C07D417/12C07D417/14C07D487/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,336,775
App. No.
15/507,375
Granted
Jul 2, 2019
Kind
B2
Abstract

The disclosure relates to compounds of formula (I) useful in the treatment of tauopathies and Alzheimer's disease wherein A, R, W, Q, n, and m are described herein.

Claims (5)

1. A compound, N-(5-(4-(1-(Benzo[d][1,3]dioxol-5-yl)ethyl)piperazin-1-yl)-1,3,4-thiadiazol-2-yl)acetamide, which is:

or any of its tautomers, enantiomers or mixtures thereof.

2. A pharmaceutically acceptable salt of a compound, N-(5-(4-(1-(Benzo[d][1,3]dioxol-5-yl)ethyl)piperazin-1-yl)-1,3,4-thiadiazol-2-yl)acetamide, which is:

or any of its tautomers or enantiomers.

3. The pharmaceutically acceptable salt of the compound of claim 2 , or any of its tautomers or enantiomers, wherein the pharmaceutically acceptable salt is acetate, adipate, alginate, arginate, aspartate, benzoate, benzenesulfonate, bisulfate, bisulfate, bromide, butyrate, camphorate, camphorsulfonate, caprate, caprylate, chloride, chlorobenzoate, citrate, cyclamate, cinnamate, cyclopentanepropionate, digluconate, dihydrogenphosphate, dinitrobenzoate, dodecylsulfate, ethanesulfonate, formate, glycolate, fumarate, galacterate, galacturonate, glucoheptanoate, gluconate, glutamate, glycerophosphate, hemisuccinate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, iodide, isethionate, isobutyrate, lactate, lactobionate, malate, maleate, malonate, mandelate, metaphosphate, methanesulfonate, methylbenzoate, monohydrogenphosphate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, oleate, palmoate, pectinate, persulfate, phenylacetate, 3-phenylpropionate, phosphate, phosphonate, or phthalate.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Feb 23, 2023
From: KREOS CAPITAL VI (UK) LIMITED
To: ASCENEURON SA
Reel/Frame 062789/0477 →
SECURITY INTEREST Recorded Mar 22, 2022
From: ASCENEURON SA
To: KREOS CAPITAL VI (UK) LIMITED
Reel/Frame 059337/0849 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 8, 2017
From: QUATTROPANI, ANNA; KULKARNI, SANTOSH S.; GIRI, AWADUT GAJENDRA
To: ASCENEURON SA
Reel/Frame 042274/0197 →
Priority Claims (1)
IN 2766/MUM/2014 · Aug 28, 2014 · national
Continuity (1)
Related Publication 20170298082A1 · Oct 19, 2017
Cited By (3)
US 12,187,741 US 12,195,455 US 12,398,130